Thread by @drkeithsiau

To celebrate the return of Hemospray, here is a summary of 3 recent Hemospray papers from the same group.

Hemospray for bleeding peptic ulcer disease (PUD) in @endoscopyjrnl

📅 Jan 16-March 19
🏥 14
🤕 202

✅ Immediate haemostasis: 88%
🩸 30d Rebleeding: 17%
⚰️ 30d Mortality: 22% (32% if monotherapy)

💡 "High immediate haemostasis rates for bleeding PUD"
thieme-connect.de/products/ejour…

Hemospray for bleeding post UGI therapy @UEGJournal

📅 Jan 16-Nov 19
🏥 16
🤕 73

✅ Immediate haemostasis: 100%
🩸 30d Rebleeding: 4%
⚰️ 30d Mortality: 2% (5% if monotherapy)

💡 "Safe and effective... with low re-bleed rate"

journals.sagepub.com/doi/full/10.11…

Hemospray for UGIB #DEN

📅 Jan 16-May 18
🏥 12
🤕 314

✅ Immediate haemostasis: 100%
🩸 30d Rebleeding: 10%
⚰️ 30d Mortality: 20% (25% if monotherapy)

💡 "Rebleeding and mortality rates were in keeping/lower than predicted rates."

onlinelibrary.wiley.com/doi/full/10.11…

My take:
🔸Avoid using Hemospray as monotherapy, esp for PUD
🔸Good for immediate haemostasis, but can cause problems for colleagues later
🔸High rebleed/mortality rates, esp if monotherapy
🔸A salami approach can cause issues with meta-analyses, esp if outcomes are repeated